Anavex announces appointment of dr. marwan n sabbagh, md as chairman of the scientific advisory board

New york, sept. 12, 2023 (globe newswire) -- anavex life sciences corp. (“anavex” or the “company”) (nasdaq: avxl), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders including alzheimer's disease, parkinson's disease, rett syndrome and other central nervous system (cns) diseases, today announced the appointment of prof. dr. marwan n sabbagh, md, as chairman of the scientific advisory board.
AVXL Ratings Summary
AVXL Quant Ranking